THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.10]-CMP133 ID: TIP-MED-000403

Oxcarbazepine IP

Active Ingredient / Scientific Identity: Oxcarbazepine IP • Class: Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Specific Analgesic & Mood Stabiliser; Potent Pan-CYP/P-gp Enzyme Inducer)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Oxcarbazepine IP ([11.10]-CMP133 | ID: TIP-MED-000403) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/11-10-cmp133-oxcarbazepine-ip/
Generic / Entity NameOxcarbazepine IP ([11.10]-CMP133)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassIminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Sp
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver di
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Oxcarbazepine IP (TIP-MED-000403, Reference Code [11.10]-CMP133) is classified under Neurology & Antiepileptic Medicines (Ch 11) as a Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic, Trigeminal Neuralgia Specific Analgesic & Mood Stabiliser; Potent Pan-CYP/P-gp Enzyme Inducer). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per Edition 2.7 p. 144 & MIG-HTML-226 (Inventory CSV mono-11-11). 10-keto analogue of Carbamazepine (Oxetol 150/300/600 mg) with weaker CYP3A4 auto-induction but higher hyponatraemia risk.
Co-indexed per Edition 2.7 p. 144 & MIG-HTML-226 (Inventory CSV mono-11-11). 10-keto analogue of Carbamazepine (Oxetol 150/300/600 mg) with weaker CYP3A4 auto-induction but higher hyponatraemia risk.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per Edition 2.7 p. 144 & MIG-HTML-226 (Inventory CSV mono-11-11). 10-keto analogue of Carbamazepine (Oxetol 150/300/600 mg) with weaker CYP3A4 auto-induction but higher hyponatraemia risk.

4. Therapeutic Indications & Evidence-Supported Uses

  • First-line Drug of Choice for Trigeminal Neuralgia (Tic Douloureux) and Glossopharyngeal Neuralgia
  • focal-onset (partial) seizures with or without secondary generalization
  • bipolar disorder maintenance

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per Edition 2.7 p. 144 & MIG-HTML-226 (Inventory CSV mono-11-11). 10-keto analogue of Carbamazepine (Oxetol 150/300/600 mg) with weaker CYP3A4 auto-induction but higher hyponatraemia risk.

Administration & Meal Timing: Take WITH meals! (Food and bile salts significantly enhance the dissolution and bioavailability of lipophilic carbamazepine and reduce GI nausea). Swallow CR/Retard tablets whole (or halved strictly along the manufacturer score line if scored pellet tablet like Tegretol-CR; never crush or chew!). | Twice daily after breakfast and dinner (for CR/Retard formulations).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [11.10].
Metabolism & Biotransformation:
Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.
Elimination & Renal Adjustment:
Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.
Hepatic Impairment Considerations:
Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • 1. MANDATORY HLA-B*15:02 PHARMACOGENOMIC WARNING IN INDIANS / SOUTH ASIANS: The HLA-B*15:02 allele (and HLA-A*31:01) is present in a significant subset of the Indian population and confers a >10- to 50-fold increased risk of fatal Carbamazepine-induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) during the first 8 weeks of therapy! 2. Contraindicated in AV Conduction Block, history of bone marrow depression, hepatic porphyria, and within 14 days of MAOIs. 3. Worsens Absence and Myoclonic Seizures!

Key Clinical Precautions: Renal: Excreted <3% unchanged; monitor sodium closely in CKD. Hepatic: Metabolised >95% hepatically; avoid in active liver disease and monitor LFTs.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Peak-concentration neurotoxicity (dizziness, vertigo, ataxia/unsteady gait, diplopia [double vision], blurred vision, nystagmus, drowsiness—markedly reduced by using Controlled-Release [CR/Retard] tablets instead of plain IR!), nausea, mild benign leukopenia (~10% of patients).
  • Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS Syndrome (90% occur within the first 14 to 60 days of starting therapy!), Severe SIADH Hyponatraemia (Na+ <125 mEq/L—especially in elderly patients and even more frequent with Oxcarbazepine!), Aplastic Anaemia and Agranulocytosis, AV nodal heart block / bradyarrhythmias in the elderly, hepatotoxicity, osteomalacia (Vitamin D catabolism).
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • POTENT PAN-INDUCER OF CYP3A4, CYP2C9, CYP1A2, UGT, AND P-GLYCOPROTEIN! Carbamazepine accelerates the hepatic breakdown and CAUSES COMPLETE THERAPEUTIC FAILURE of: • Direct Oral Anticoagulants (Apixaban, Rivaroxaban, Dabigatran—CONTRAINDICATED, causes stroke/clots!) and Warfarin (drops INR by 50%!)
    • • Calcium Channel Blockers (Amlodipine, Nimodipine, Felodipine), Statins (Atorvastatin, Simvastatin), Corticosteroids (Prednisolone, Dexamethasone), Levothyroxine, Cyclosporine/Tacrolimus, Oral Contraceptives, Itraconazole, Doxycycline, and Haloperidol/Risperidone/Quetiapine! 2
    • CYP3A4 Inhibitors that Cause Acute Carbamazepine Toxicity (ataxia, double vision, coma): Clarithromycin, Erythromycin, Fluconazole, Itraconazole, Verapamil, Diltiazem, Cimetidine, and Sodium Valproate (Valproate inhibits epoxide hydrolase, causing toxic accumulation of active Carbamazepine-10,11-epoxide even when parent carbamazepine levels look normal!)

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [11.10].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: 1. Always dispense Controlled-Release (Tegretol-CR / Mazetol-SR / Zeptol-CR) when specified—switching a patient from CR to plain IR causes sudden spikes of double vision and staggering 2 hours after each dose! 2. Urgent SJS Skin & Blood Warning: Instruct the patient to stop the tablet and report to the emergency room immediately if any skin rash, fever, sore throat, mouth/lip blisters, red eyes, or easy bruising develops (especially during the first 2 months). 3. Check if the patient is taking any blood thinner (Apixaban/Rivaroxaban/Warfarin) or Amlodipine/Atorvastatin, as Carbamazepine destroys their levels in the body!
    • Meal & Clock Timing Instruction: Take WITH meals! (Food and bile salts significantly enhance the dissolution and bioavailability of lipophilic carbamazepine and reduce GI nausea). Swallow CR/Retard tablets whole (or halved strictly along the manufacturer score line if scored pellet tablet like Tegretol-CR; never crush or chew!). (Twice daily after breakfast and dinner (for CR/Retard formulations).)
    • Missed Dose Protocol: Take with food as soon as remembered unless within 4–6 hours of next scheduled dose; never double.
    • Geriatric Dispensing Pearl: In elderly CGHS patients prescribed Carbamazepine (or Oxcarbazepine) for Trigeminal Neuralgia, monitor closely for three major geriatric hazards: (1) Severe Hyponatraemia (SIADH) (especially if also taking a thiazide diuretic or SSRI!), (2) Bradycardia/AV heart block, and (3) Loss of efficacy of their concurrent anticoagulant and antihypertensive drugs.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release Tablets: 100 mg, 200 mg, 400 mg; Controlled/Sustained-Release (CR/SR/Retard) Scored Tablets: 200 mg, 300 mg, 400 mg; Oral Syrup: 100 mg/5 mL

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    ← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
    Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/11-10-cmp133-oxcarbazepine-ip/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.